



Moment of Clarity Publishes In-Depth Resource Exploring the Success Rate of Spravato Treatment

November 18, 2025

Huntington Beach, California - November 18, 2025 -

Moment of Clarity has published a new educational article titled "What Is the Spravato Success Rate?" which examines recent clinical findings on the effectiveness of Spravato (esketamine) therapy for people living with treatment-resistant depression. The publication, available on the Moment of Clarity website, provides data-driven insights into how this FDA-approved treatment works, its clinical outcomes, and its role in comprehensive mental health care.

The article highlights that Spravato, a nasal spray derived from esketamine, is specifically designed for patients who have not responded to conventional antidepressants. According to research published in *The American Journal of Psychiatry*, approximately 70% of patients receiving esketamine in conjunction with oral antidepressants reported measurable symptom improvement, and nearly half achieved partial or complete remission after four weeks of treatment. The Moment of Clarity resource contextualizes these findings within real-world clinical settings, emphasizing that success rates can vary depending on a patient's treatment history, concurrent therapy participation, and medical supervision.

Moment of Clarity's publication underscores that Spravato is most effective when integrated into a comprehensive care model that includes psychiatric evaluation, therapy, and medication management. The National Institute of Mental Health (NIMH) reports that treatment-resistant depression affects an estimated 30% of people with major depressive disorder, making evidence-based therapies like Spravato increasingly crucial in modern psychiatry.

In alignment with best practices from the Substance Abuse and Mental Health Services Administration (SAMHSA), Moment of Clarity incorporates multiple treatment modalities within its mental health programs, including cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), trauma-informed therapy, and ketamine-assisted therapy. The publication explains that the combination of medical and psychotherapeutic care produces more sustainable outcomes by addressing both neurological and behavioral components of depression.

The resource further examines how Spravato differs from traditional antidepressant medications. While conventional treatments primarily focus on regulating serotonin and dopamine, esketamine acts on the brain's glutamate system—the largest excitatory neurotransmitter network. Studies published in *Nature Neuroscience* demonstrate that this mechanism promotes synaptic growth, helping to restore neural communication disrupted by chronic depression. The result is faster symptom relief, often within days rather than weeks.

Moment of Clarity's new resource also highlights the importance of psychiatric evaluation in determining patient eligibility for Spravato therapy. Each patient undergoes a comprehensive assessment with the outpatient mental health treatment center to ensure the treatment aligns with their diagnosis, medication history, and overall health status. Medical professionals then monitor patients during each Spravato session, tracking both physical and psychological responses. This structured process aligns with safety protocols recommended by the U.S. Food and Drug Administration (FDA) and by clinical researchers studying the long-term effects of esketamine.

In neighborhoods such as Oak View, Ocean Breeze, Fountain Valley North, Mesa Verde, and South Coast Metro, growing awareness around treatment-resistant depression has led many patients to seek innovative, medically supervised treatments. The Moment of Clarity publication explains that outpatient and intensive outpatient (IOP) mental health centers provide flexible, evidence-based care that accommodates patients' personal and professional lives. These treatment models align with data published in the *Psychiatric Services Journal*, which indicates that patients who receive multidisciplinary outpatient support report higher long-term recovery rates compared to those relying solely on medication.

The article also discusses how ketamine-assisted therapy complements Spravato's effects by providing a

therapeutic setting that encourages emotional processing and cognitive restructuring. Research from *Frontiers in Psychiatry* suggests that pairing ketamine-based interventions with psychotherapy enhances neuroplasticity and self-awareness, helping patients sustain improvement after treatment. The Moment of Clarity resource places this data within a broader discussion of holistic mental health care, reinforcing that recovery requires both scientific precision and compassionate guidance.

For people in Fountain Valley North and Mesa Verde exploring psychiatric evaluation for mental health conditions or seeking alternatives to conventional antidepressants, the resource provides accessible, verified information. It emphasizes that while Spravato represents a significant step forward in mental health treatment, success depends on consistency, professional supervision, and an integrated approach that includes therapy and medication management.

Moment of Clarity's publication also touches on accessibility, noting that insurance coverage for Spravato and related treatments is expanding as more research validates their safety and efficacy. The *Journal of Clinical Psychopharmacology* reports that insurance utilization of esketamine-based therapies has increased by 200% over the past three years, reflecting a broader recognition among healthcare providers.

By publishing "What Is the Spravato Success Rate?", Moment of Clarity contributes to ongoing efforts to educate patients, families, and mental health professionals about evidence-based treatments for depression. The article reinforces the organization's dedication to clinical accuracy, safety, and public awareness of emerging therapies that offer hope to those living with chronic mood disorders.

Residents in and around Huntington Beach—including Oak View, Ocean Breeze, Fountain Valley North, Mesa Verde, and South Coast Metro—can learn more about Spravato therapy, psychiatric evaluation, and ketamine-assisted programs by visiting the Moment of Clarity Huntington Beach. The new resource serves as a fact-based guide to help patients make informed decisions about their mental health treatment options.

<https://www.youtube.com/shorts/IAa4dBvjJDQ>

###

For more information about Moment of Clarity Huntington Beach, contact the company here: Moment of Clarity Huntington Beach Marie Mello (949) 403-6740 marie@momentofclarity.com

Moment of Clarity Huntington Beach

Huntington Beach, CA's preferred mental health treatment facility. Whether you are struggling with anxiety, depression,

dual diagnosis disorder, eating disorders, or general unrest, call Moment of Clarity.

Website: <https://momentofclarity.com/>

Email: marie@momentofclarity.com

Phone: (949) 403-6740

